CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Has Average Price Target of $10.44 According to Brokerages

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $10.44.

CAMP has been the topic of a number of recent analyst reports. Zacks Research upgraded shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Needham & Company LLC assumed coverage on CAMP4 Therapeutics in a report on Thursday, October 15th. They set a “buy” rating and a $8.00 price objective for the company. Wall Street Zen cut shares of CAMP4 Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Oppenheimer started coverage on shares of CAMP4 Therapeutics in a research report on Monday, October 5th. They issued an “outperform” rating and a $15.00 price target on the stock. Finally, UBS Group set a $15.00 target price on CAMP4 Therapeutics in a report on Friday, August 14th.

Insider Transactions at CAMP4 Therapeutics

In other news, Director Richard Young acquired 16,378 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the acquisition, the director owned 186,388 shares in the company, valued at $307,540.20. This represents a 9.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Kelly Gold purchased 10,000 shares of the firm’s stock in a transaction dated Monday, August 31st. The shares were acquired at an average cost of $3.96 per share, with a total value of $39,600.00. Following the completion of the purchase, the chief financial officer directly owned 10,000 shares in the company, valued at approximately $39,600. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders bought 46,031 shares of company stock valued at $99,051 and sold 593,613 shares valued at $2,504,037. 21.69% of the stock is owned by insiders.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Jupiter Topco LLC acquired a new position in CAMP4 Therapeutics during the second quarter worth approximately $27,581,000. 5AM Venture Management LLC bought a new stake in shares of CAMP4 Therapeutics in the second quarter valued at approximately $25,647,928. Trails Edge Capital Partners LP bought a new stake in shares of CAMP4 Therapeutics during the 2nd quarter valued at $8,446,935. BlackRock Inc. acquired a new stake in CAMP4 Therapeutics during the second quarter worth about $7,185,000. Finally, SummitTX Capital L.P. bought a new position in CAMP4 Therapeutics in the first quarter valued at approximately $1,497,000.

CAMP4 Therapeutics Stock Performance

NASDAQ:CAMP opened at $3.30 on Friday. The company has a 50-day moving average of $3.99 and a 200-day moving average of $4.13. The company has a market capitalization of $207.08 million, a price-to-earnings ratio of -1.42 and a beta of 0.27. CAMP4 Therapeutics has a 52 week low of $2.90 and a 52 week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million during the quarter. Sell-side analysts forecast that CAMP4 Therapeutics will post -0.66 EPS for the current year.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing medicines that increase the production of disease-relevant proteins by activating the expression of specific genes. The company’s approach is designed to address diseases caused by insufficient protein levels, including certain genetic disorders in which boosting activity from a functional gene copy may provide therapeutic benefit.

CAMP4 uses its Regulatory Action Platform, or RAP, to identify regulatory elements that control RNA production and discover small-molecule compounds capable of increasing the expression of selected genes.